| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d0805c8b8024105a3991ca1628c9bf14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ba8ac4026f40d9ade8e9f6ff12ee6b60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bc2b03342511abc88f60c63f2acd96d0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3231
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1131
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02 |
| filingDate |
2021-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3154b381bfe3d7470bd45be4361d68d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a2868da3be9ac016f08ca3f6d433ca9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_daf9baf356055e95c3b3be1bf53c98ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3447eb1444dd8442121501eb21145dab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_712cc8673d973649fb18555b6ec086c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64d466569230a0d3e894c1e0c7d309ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22cfde067b4efd8ba50852dccdfe784b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d05124dbb0f048d15fe4458c5c84fbb |
| publicationDate |
2021-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021188931-A1 |
| titleOfInvention |
Anti-coronaviral compositions and methods of using the same |
| abstract |
Methods of inhibiting a coronavirus (CoV) in a sample are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a conserved RNA secondary structure of CoV with an effective amount of an agent that specifically binds to the secondary structure to inhibit the CoV. Also provided are methods of treating or preventing CoV infection in a subject. Methods of treating or preventing a neoplastic condition in a subject are also provided. The neoplastic condition can include lung cancer. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a secondary structure of a CoV that find use in the subject methods. |
| priorityDate |
2020-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |